The RANKL/RANK/OPG system plays a critical role in regulating bone modeling and remodeling. RANKL promotes osteoclast formation, activation, and survival, while OPG inhibits RANKL activity, thereby protecting bone from excessive resorption. The balance between RANKL and OPG determines bone mass and strength. In normal bone remodeling, osteoclasts resorb bone, and osteoblasts form new bone, maintaining skeletal integrity. In pathological conditions, such as osteoporosis and rheumatoid arthritis, this balance is disrupted, leading to increased bone resorption. RANKL is expressed by chondrocytes and osteoblasts, and its expression is regulated by factors such as BMP2 and Vitamin D3. RANKL signaling is essential for endochondral ossification, the process by which bone is formed from cartilage. RANKL also plays a role in immune responses, linking bone biology with immunology. RANK, the receptor for RANKL, is expressed in osteoclasts, osteoblasts, and other cells, and its signaling is crucial for osteoclastogenesis and immune cell development. OPG, a decoy receptor for RANKL, inhibits osteoclast formation and is involved in regulating bone remodeling. RANKL signaling is also involved in the regulation of osteoclast function, including their fusion, resorption activity, and interaction with other cells. RANKL can induce osteoclast formation directly or indirectly through the activation of osteoblastic cells. In addition to bone, RANKL signaling is involved in other physiological processes, such as tumor cell proliferation and immune responses. The discovery of RANKL, RANK, and OPG has led to the development of therapeutic agents, such as Denosumab, which inhibit RANKL signaling and are used to treat bone diseases. Overall, the RANKL/RANK/OPG system is essential for maintaining skeletal homeostasis and is involved in a wide range of physiological and pathological processes. Understanding this system is crucial for developing new treatments for bone diseases and related conditions.The RANKL/RANK/OPG system plays a critical role in regulating bone modeling and remodeling. RANKL promotes osteoclast formation, activation, and survival, while OPG inhibits RANKL activity, thereby protecting bone from excessive resorption. The balance between RANKL and OPG determines bone mass and strength. In normal bone remodeling, osteoclasts resorb bone, and osteoblasts form new bone, maintaining skeletal integrity. In pathological conditions, such as osteoporosis and rheumatoid arthritis, this balance is disrupted, leading to increased bone resorption. RANKL is expressed by chondrocytes and osteoblasts, and its expression is regulated by factors such as BMP2 and Vitamin D3. RANKL signaling is essential for endochondral ossification, the process by which bone is formed from cartilage. RANKL also plays a role in immune responses, linking bone biology with immunology. RANK, the receptor for RANKL, is expressed in osteoclasts, osteoblasts, and other cells, and its signaling is crucial for osteoclastogenesis and immune cell development. OPG, a decoy receptor for RANKL, inhibits osteoclast formation and is involved in regulating bone remodeling. RANKL signaling is also involved in the regulation of osteoclast function, including their fusion, resorption activity, and interaction with other cells. RANKL can induce osteoclast formation directly or indirectly through the activation of osteoblastic cells. In addition to bone, RANKL signaling is involved in other physiological processes, such as tumor cell proliferation and immune responses. The discovery of RANKL, RANK, and OPG has led to the development of therapeutic agents, such as Denosumab, which inhibit RANKL signaling and are used to treat bone diseases. Overall, the RANKL/RANK/OPG system is essential for maintaining skeletal homeostasis and is involved in a wide range of physiological and pathological processes. Understanding this system is crucial for developing new treatments for bone diseases and related conditions.